/
ELUT
$0.96-$0.04 (-4.25%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$44.2M
44M shares
52-week range
$0.50 – $2.64
21% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
3.77%
Moderate
Price (6 mo)
Loading chart…
Change$-0.47
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $39.0M | $42.9M | $42.7M | $47.4M | $23.8M | $24.7M | $24.4M | $12.3M |
| Cost of revenue | $23.1M | $23.1M | $22.1M | $28.4M | $12.2M | $13.7M | $13.7M | $5.7M |
| Gross profit | $15.9M | $19.8M | $20.6M | $19.0M | $11.6M | $11.1M | $10.7M | $6.6M |
| Gross margin | 40.8% | 46.1% | 48.2% | 40.1% | 48.8% | 44.7% | 43.9% | 53.7% |
| R&D | $2.5M | $2.4M | $6.0M | $9.3M | $7.7M | $4.4M | $3.8M | $4.2M |
| Operating income | −$8.2M | −$8.4M | −$13.6M | −$23.0M | −$35.2M | −$30.5M | −$35.7M | −$18.4M |
| EBITDA | −$2.2M | −$2.7M | −$12.3M | −$15.7M | −$27.3M | −$31.9M | −$45.9M | −$13.5M |
| Net income | −$11.6M | −$11.9M | −$21.8M | −$24.8M | −$32.9M | −$37.7M | −$53.9M | $53.4M |
| Net margin | -29.6% | -27.8% | -51.1% | -52.4% | -137.9% | -152.2% | -221.3% | 434.2% |
| EPS (diluted) | -1.08 | -1.12 | -2.13 | -2.38 | -2.38 | -2.07 | -1.86 | -0.79 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $12M | $-0.60 | $-0.60–$-0.60 | 1 |
| 2027 | $13M | $-0.52 | $-0.52–$-0.52 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.07
Price
$0.96
Implied downside
-93%
Peer comparison
Elutia Inc. Class A Common Stock
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.
www.elutia.com- Employees
- 26
- IPO / List date
- Oct 8, 2020
- HQ
- SILVER SPRING, MD
Held by traders on TradeandTell
No one on the platform currently holds ELUT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 82,716 | $86.9K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ELUT yet.
